|
gptkbp:instanceOf
|
gptkb:company
|
|
gptkbp:CEO
|
gptkb:Thomas_Glanzmann
|
|
gptkbp:country
|
gptkb:Spain
|
|
gptkbp:ESRB_rating
|
MSCI BBB (2023)
|
|
gptkbp:founded
|
1940
|
|
gptkbp:founder
|
gptkb:Jose_Antonio_Grifols_Roig
|
|
gptkbp:headquartersLocation
|
gptkb:Barcelona,_Spain
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Grifols
|
|
gptkbp:industry
|
gptkb:biotechnology
pharmaceuticals
|
|
gptkbp:ISIN
|
ES0171996087
|
|
gptkbp:legalForm
|
Sociedad Anónima
|
|
gptkbp:listedOn
|
gptkb:IBEX_35
|
|
gptkbp:marketCap
|
~€6 billion (2024)
|
|
gptkbp:notableAcquisition
|
gptkb:Biotest_AG_(2022)
Talecris Biotherapeutics (2011)
|
|
gptkbp:notableEvent
|
Acquired Biotest AG in 2022
Acquired Talecris Biotherapeutics in 2011
Expanded to the US market in 2003
Founded as a blood plasma company in 1940
|
|
gptkbp:notableProduct
|
gptkb:alpha-1_antitrypsin
gptkb:antithrombin
immune response
albumin
diagnostic reagents
coagulation factors
blood typing systems
hospital pharmacy solutions
|
|
gptkbp:numberOfEmployees
|
~24,000
|
|
gptkbp:parentCompany
|
gptkb:Grifols,_S.A.
|
|
gptkbp:products
|
diagnostic systems
hospital equipment
plasma-derived medicines
|
|
gptkbp:publiclyTraded
|
yes
|
|
gptkbp:revenue
|
€6.1 billion (2023)
|
|
gptkbp:servesArea
|
worldwide
|
|
gptkbp:stockExchange
|
gptkb:BME
|
|
gptkbp:stockSymbol
|
gptkb:GRF
|
|
gptkbp:subsidiary
|
gptkb:Talecris_Biotherapeutics
gptkb:Biotest_AG
|
|
gptkbp:website
|
https://www.grifols.com
|
|
gptkbp:主要业务
|
bioscience
diagnostics
plasma collection
bio supplies
hospital division
plasma fractionation
|
|
gptkbp:bfsParent
|
gptkb:Orient_Hontai_Capital
gptkb:City_of_Emeryville
gptkb:Talecris_Biotherapeutics
|
|
gptkbp:bfsLayer
|
7
|